Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of HER3-DXd (U3-1402) in Metastatic or Unresectable NSCLC
jRCT2080224788Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jul 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 1, open-label trial of patritumab deruxtecan in non-small cell lung cancer (NSCLC) (7 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Safety and tolerability of HER3-DXd and Maximum tolerated dose / recommended dose. Started Jul 2019; status: completed.
02
Drugs
patritumab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080224788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224788.